157 related articles for article (PubMed ID: 28530515)
1. Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
Tsiachristas A; Gittins M; Kitchener H; Gray A
J Med Screen; 2018 Jun; 25(2):99-109. PubMed ID: 28530515
[TBL] [Abstract][Full Text] [Related]
2. A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
Kitchener HC; Gittins M; Rivero-Arias O; Tsiachristas A; Cruickshank M; Gray A; Brabin L; Torgerson D; Crosbie EJ; Sargent A; Roberts C
Health Technol Assess; 2016 Sep; 20(68):1-138. PubMed ID: 27632816
[TBL] [Abstract][Full Text] [Related]
3. A cluster randomized trial of strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC trial.
Kitchener H; Gittins M; Cruickshank M; Moseley C; Fletcher S; Albrow R; Gray A; Brabin L; Torgerson D; Crosbie EJ; Sargent A; Roberts C
J Med Screen; 2018 Jun; 25(2):88-98. PubMed ID: 28530513
[TBL] [Abstract][Full Text] [Related]
4. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review.
Mohan G; Chattopadhyay S
JAMA Oncol; 2020 Sep; 6(9):1434-1444. PubMed ID: 32556187
[TBL] [Abstract][Full Text] [Related]
6. Economics of Multicomponent Interventions to Increase Breast, Cervical, and Colorectal Cancer Screening: A Community Guide Systematic Review.
Mohan G; Chattopadhyay SK; Ekwueme DU; Sabatino SA; Okasako-Schmucker DL; Peng Y; Mercer SL; Thota AB;
Am J Prev Med; 2019 Oct; 57(4):557-567. PubMed ID: 31477431
[TBL] [Abstract][Full Text] [Related]
7. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
8. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
11. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
12. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
13. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
14. The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.
Burger EA; Sy S; Nygård M; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2017 Jan; 26(1):95-103. PubMed ID: 27624639
[TBL] [Abstract][Full Text] [Related]
15. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis.
Messoudi W; Elmahi T; Nejjari C; Tachfouti N; Zidouh A; Saadani G; Moriña D; Diaz M
J Med Econ; 2019 Nov; 22(11):1153-1159. PubMed ID: 31135231
[No Abstract] [Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]